Format

Send to

Choose Destination
Gynecol Oncol. 2016 Apr;141(1):65-71. doi: 10.1016/j.ygyno.2016.01.003.

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
2
Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: swestin@mdanderson.org.

Abstract

Precision medicine is a rapidly evolving area in the treatment of gynecologic malignancies. Advances in sequencing technology have resulted in an increasing wealth of data regarding the genomic characteristics of ovarian, endometrial, and cervical cancers. These vast new datasets of information have led to novel insights into potential vulnerabilities and therapeutic targets for these cancers. However, unraveling the complex molecular changes within cancer cells to determine how best to attack these targets and to identify effective biomarkers of response remains a significant challenge. In this article, we review the current status of biomarker-driven targeted therapy in gynecologic malignancies.

KEYWORDS:

Biomarkers; Gynecologic cancer; Personalized medicine; Precision medicine; Targeted therapy

PMID:
27016231
PMCID:
PMC4808566
DOI:
10.1016/j.ygyno.2016.01.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center